Fresenius Medical Care (FMS) is rated a buy, with shares up 32.95% YoY and strong Q1 2025 results, showing 60% (YoY) net income growth. My valuation using a forward P/S ratio suggests FMS is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback